Breast cancer model

To evaluate PARP inhibition in a realistic setting, olaparib (7) was tested in a BrcflI / p53 / mouse breast cancer model. Treatment with olaparib caused tumor growth inhibition without generating signs of toxicity [14]. Interestingly, upon cessation of treatment and tumor... 

Other compounds, such as ZK-703 and ZK-253, are currently under preclinical testing, and preliminary data show a pure antiestrogen activity in xenograft breast cancer models (Hoffmann et al. 2004). 

W. Schiesi. Hyaluromdase enhances the activity of adrlamycin in breast cancer models In vitio and in vivo. J. Cancer Res. Clin. Oncol- J18 591 (1992). 

Chen, J-H., Ling, R Yao, Q Li, Y Chen, T. Wang, Z., and Li, K-Z. (2005), Effect of small-sized liposomal adriamycin administered by various routes on a metastatic breast cancer model, Endocr.-Related Cancer, 12, 93-100. 

Hiraga, T., Williams, P.J., Ueda, A., Tamura, D., and Yoneda, T. (2004). Zoledronic acid inhibits visceral metastases in the 4Tl/luc mouse breast cancer model. Clin Cancer Res 10 4559 567. 

Colbern, G.T. Hiller, A.J. Musterer, R.S. Working, P.K. Henderson, LC. Antitumor activity of herceptin in combination with stealth liposomal cisplatin or non-liposomal cisplatin in a HER2 positive human breast cancer model. J. Inorg. Biochem. 1999, 77, 117-120. 

Triptolide has been shown to induce apoptosis of several human cancer cell lines grown in culture and to inhibit tumor development in a murine breast cancer model " but has shown toxicity at high doses. The 14-succinyl sodium salt of triptolide (34), known as PG490-88, suppresses tumor growth without toxicity and has entered Phase I clinical trials the data is summarized as follows Our results suggest a potential role of PG490-88 alone and in combination with chemotherapy as a novel antineoplastic regimen for the treatment of patients with solid tumors. ... 

Azuma, H., Takahara, S., Ichimaru, N., Wang, J. D., Itoh, Y., Otsuki, Y., Morimoto, J., Fukui, R., Hoshiga, M., Ishihara, T., Nonomura, N., Suzuki, S., Okuyama, A., Katsuoka, Y. Marked prevention of tumor growth and metastasis by a novel immunosuppressive agent, FTY720, in mouse breast cancer models. Cancer Res 62 (2002) 1410-1419. 

New medical applications of yttrium include Taxol and °Y-labeled DOTA-pep-tide-ChL6 as radioimmunoconconjugates for targeting ionizing radiation to breast cancer model HBT 3477 (DeNardo etal.1997), as well as modem endoscopy therapy using a YAG laser (Alsolarman et al. 2002). 

Kouros-Mehr H, Bechis SK, Slorach EM, Littlepage LE, Egeblad M, Ewald AJ, Pai SY, Ho IC, Werb Z. GATA-3 links tumor differentiation and dissemination in a luminal breast cancer model. Cancer Cell 2008 13 141-152. 

Desai KV, Xiao N, Wang W, Gangi L, Greene J, Powell JI, Dickson R, Furth P, Hunter K, Kucherlapati R, Simon R, Liu ET, Green JE. Initiating oncogenic event determines gene-expression patterns of human breast cancer models. Proc Natl Acad Sci USA 2002 99 6967-6972. 

Lin EY, Jones JG, Li P, Zhu L, Whitney KD, Muller WJ, Pollard JW. Progression to malignancy in the polyoma middle T oncoprotein mouse breast cancer model provides a reliable model for human diseases. Am J Pathol 2003 163 2113-2126. 

Durfort T, Tkach M, Meschaninova Ml, Rivas MA, Elizalde PV, Venyaminova AG, Schillaci R, Franqois JC. Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model. PLoS One. 2012 7(l) e29213. 

Emtage, P. C., Wan, Y., Hitt, M., Graham, F. L., Muller, W. J., Zlotnik, A., and Gauldie, J. (1999). Adenoviral vectors expressing lymphotactin and interleukin 2 or lymphotactin and interleukin 12 synergize to facilitate tumor regression in murine breast cancer models. Him. Gene. Ther. 10, 697-709. 

L. E. van Vlerken et ah, Biodistribution and pharmacokinetic analysis of paclitaxel and ceramide administered in multifunctional polymer-blend nanoparticles in drug resistant breast cancer model. Mol. Pharm. (2008). 

For breast and thyroid cancer as well as for leukemia, different models were chosen by BEIR VII. The breast cancer model is based on a pooled analysis of data from eight breast cancer incidence studies by Preston et al. (2002). The thyroid cancer model is based on a pooled analysis of data from seven thyroid cancer incidence studies by Ron et al. (1995). For leukemia, the BEIR VII model includes a time, t (= a-e), since exposure dependence (decreasing with increasing t) and a finear-qua-dratic function of dose. 

The combination of intravenously administered folate-liposome-anti-HER-2 antisense ODN (AS HER-2 ODN) complex and docetaxel resulted in a marked inhibition of xenograft growth in an aggressive breast cancer model that does not overexpress HER-2, even after treatment ended (Rait et al. 2002). 

For PET imaging purposes, F-labeled VIP has been evaluated in a preliminary study with a breast cancer model, where it demonstrated low tumor uptake compared with FDG (144). 

---